PR Newswire Clinical TrialsOriginal article
Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy
Phase 3positiveVYEPTIPositive
AI Analysis
Summary
Lundbeck announced positive Phase IV THRIVE trial results for VYEPTI (eptinezumab) in migraine patients with inadequate response to prior CGRP-targeting preventive therapy, with 60% of participants reporting significant improvement. The trial met its primary endpoint in this previously treatment-refractory population.
Clinical Trial Data
Phase
Phase IV
Primary Endpoint
Met
Outcome Details
60% of participants reported being 'much improved' or 'very much improved' following treatment; primary endpoint met
Importance:6/10
Sentiment:
0.70
CGRP antagonistmigraineclinical trialpositive resultsinadequate response population
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 1, 2026 6:22 AM